Hanna Szwed
Research Subjects
Research Interests
Hanna Szwed has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Ilona Kowalik
22 shared publications- Maciej Sterliński
1st Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
14 shared publications - Rafał Dąbrowski
Department of Coronary Artery Disease and Cardiac Rehabilitation, National Institute of Cardiology, 04-628 Warsaw, Poland
14 shared publications - Aleksander Maciag
2nd Coronary Disease Depar tment, Institute of Car diology, Warsaw, Poland.
12 shared publications - Michał Lewandowski
2nd Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
10 shared publications - Edyta Smolis-Bąk
Department of Coronary Artery Disease and Cardiac Rehabilitation, National Institute of Cardiology, 04-628 Warsaw, Poland
8 shared publications
Latest Publications
- 28 February 2022
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 80 (2) , 247-248
Professor Robert H Jones (1940–2022)
- 28 February 2022
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 80 (2) , 247-248
Professor Robert H Jones (1940–2022)
- Open Access
- 12 May 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-7
Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
- 12 May 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-7
Open AccessClinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
- 31 January 2017
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 61-62
Incessant form of a benign arrhythmia in a patient with a DDD pacemaker.
Authors present the case of an 83-year old male with the dual chamber pacemaker implanted due to a tachycardia-bradycardia syndrome and with an incessant form of atrioventricular nodal re-entrant tachycardia (AVNRT). Intracardiac electrogram with the retrograde atrial depolarization helps to...
- 31 January 2017
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 61-62
Incessant form of a benign arrhythmia in a patient with a DDD pacemaker.
Authors present the case of an 83-year old male with the dual chamber pacemaker implanted due to a tachycardia-bradycardia syndrome and with an incessant form of atrioventricular nodal re-entrant tachycardia (AVNRT). Intracardiac electrogram with the retrograde atrial depolarization helps to...
- Open Access
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Open AccessComparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- Open Access
- 11 September 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 162
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within minutes of administration.
- 11 September 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 162
Open AccessClinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within minutes of administration.
- 1 January 2012
- Vol. 70 (4) , 360-8
QRS complex widening as a predictor of appropriate implantable cardioverter-defibrillator (ICD) therapy and higher mortality risk in primary prevention ICD patients.
Effectiveness of implantable cardioverter-defibrillators (ICD) in patients with reduced left ventricular ejection fraction after myocardial infarction has been documented in large randomised trials. We analysed the predictive value of clinical factors at the time of implantation for adequate ICD interventions and mortality risk. We analysed 121 consecutive patients (15 women, 106 [88%] men; mean age 62 ± 10 years) with coronary artery disease in whom ICD was implanted for primary prevention between 2001 and 2007. Mean duration of follow-up was 876 ± 538 days. Forty-four (36.4%) patients had adequate ICD interventions. In the Cox analysis, wider QRS complexes (hazard ration [HR] per each 10 ms increment: 1.13, confidence interval [CI] 1.039-1.229, p = 0.0045) and younger age at the time of ICD implantation (HR per each 10 year increment: 0.7, CI 0.5-0.9, p = 0.0081) were associated with a higher probability of adequate intervention. Wider QRS complexes were associated with a higher probability of electrical storm (HR 1.059, CI 1.014-1.045, p = 0.0002). During follow-up, 21 (17.4%) patients died. In the Cox analysis, wider QRS complexes (HR per each 10 ms increment: 1.123, CI 1.011-1.248, p = 0.0306 [in univariate analysis only]), older age at the time of implantation (HR per each 10 year increment: 1.7, CI 1.1-2.8, p = 0.0396) and higher NYHA class (HR 4.4, CI 1.7-11.5, p = 0.0022) were associated with increased mortality. Mortality was reduced by previous revascularisation (HR 0.3, CI 0.1-0.7, p = 0.006). Patients with wider QRS complexes at the time of ICD implantation had a higher probability of adequate device intervention and mortality risk. QRS complex widening was also associated with a higher incidence of electrical storm.
- 1 January 2012
- Vol. 70 (4) , 360-8
QRS complex widening as a predictor of appropriate implantable cardioverter-defibrillator (ICD) therapy and higher mortality risk in primary prevention ICD patients.
Effectiveness of implantable cardioverter-defibrillators (ICD) in patients with reduced left ventricular ejection fraction after myocardial infarction has been documented in large randomised trials. We analysed the predictive value of clinical factors at the time of implantation for adequate ICD interventions and mortality risk. We analysed 121 consecutive patients (15 women, 106 [88%] men; mean age 62 ± 10 years) with coronary artery disease in whom ICD was implanted for primary prevention between 2001 and 2007. Mean duration of follow-up was 876 ± 538 days. Forty-four (36.4%) patients had adequate ICD interventions. In the Cox analysis, wider QRS complexes (hazard ration [HR] per each 10 ms increment: 1.13, confidence interval [CI] 1.039-1.229, p = 0.0045) and younger age at the time of ICD implantation (HR per each 10 year increment: 0.7, CI 0.5-0.9, p = 0.0081) were associated with a higher probability of adequate intervention. Wider QRS complexes were associated with a higher probability of electrical storm (HR 1.059, CI 1.014-1.045, p = 0.0002). During follow-up, 21 (17.4%) patients died. In the Cox analysis, wider QRS complexes (HR per each 10 ms increment: 1.123, CI 1.011-1.248, p = 0.0306 [in univariate analysis only]), older age at the time of implantation (HR per each 10 year increment: 1.7, CI 1.1-2.8, p = 0.0396) and higher NYHA class (HR 4.4, CI 1.7-11.5, p = 0.0022) were associated with increased mortality. Mortality was reduced by previous revascularisation (HR 0.3, CI 0.1-0.7, p = 0.006). Patients with wider QRS complexes at the time of ICD implantation had a higher probability of adequate device intervention and mortality risk. QRS complex widening was also associated with a higher incidence of electrical storm.
- 1 January 2011
- Vol. 69 (4) , 346-54
Successful primary coronary angioplasty improves early and long-term outcomes in ST segment elevation acute coronary syndromes in patients above 80 years of age.
ST segment elevation myocardial infarction (STEMI) in patients above 80 years of age continues to be a therapeutic challenge. Patients in this age group are rarely included in randomised clinical trials. Comparison of the effectiveness and safety of STEMI management in octogenarians in hospitals with a 24-hour percutaneous coronary intervention (PCI) capability and hospitals without PCI access. A retrospective analysis of medical records of 50 octogenarians who were treated with PCI (group 1) in one center and 50 patients treated noninvasively in the other 3 hospitals (group 2). We evaluated mortality and major adverse cardiac events after 10 days, 30 days and 1 year. There were no significant differences in the demographic characteristics of the study groups. The duration of coronary pain was similar in both groups: 318 min in group 1 vs 383 min in group 2 (NS). Mortality in group 2 was significantly higher than in group 1: 40% vs 14%, respectively, after 10 days (p = 0.0034); 48 vs 18% after 30 days (p = 0.0014); and 54% vs 24% after 1 year (p = 0.0021). Thrombolytic treatment was used in only 40% of the patients in group 2. In group 2, acute heart failure (HF) (Killip class III and IV) was diagnosed more frequently than in group 1 (28% vs 12%, p = 0.034). In patients with Killip class I/II HF, mortality in patients in group 2 and group 1 was 22% vs 9%, at 10 days; 31% vs 14% at 30 days; and 39% vs 20% at 1 year. In patients with Killip class III/IV HF, mortality was 86% vs 50%, at 10 days; 93% vs 50% at 30 days; and 93% vs 50% at 1 year, respectively (all differences NS). In multivariate analysis adjusted for the differences between groups, HF (a negative effect) and a successful PCI (a positive effect) were independent predictors of 1-year survival. Successful primary PCI in STEMI patients above 80 years of age resulted in a reduction of early and long-term mortality compared to the medically treated patients. The benefits of PCI treatment accrued during the follow-up. In patients treated in the tertiary reference centre in whom PCI was not successful or was not deemed feasible, prognosis was similar to that in the medically treated patients. The latter patients rarely received thrombolytic treatment.
- 1 January 2011
- Vol. 69 (4) , 346-54
Successful primary coronary angioplasty improves early and long-term outcomes in ST segment elevation acute coronary syndromes in patients above 80 years of age.
ST segment elevation myocardial infarction (STEMI) in patients above 80 years of age continues to be a therapeutic challenge. Patients in this age group are rarely included in randomised clinical trials. Comparison of the effectiveness and safety of STEMI management in octogenarians in hospitals with a 24-hour percutaneous coronary intervention (PCI) capability and hospitals without PCI access. A retrospective analysis of medical records of 50 octogenarians who were treated with PCI (group 1) in one center and 50 patients treated noninvasively in the other 3 hospitals (group 2). We evaluated mortality and major adverse cardiac events after 10 days, 30 days and 1 year. There were no significant differences in the demographic characteristics of the study groups. The duration of coronary pain was similar in both groups: 318 min in group 1 vs 383 min in group 2 (NS). Mortality in group 2 was significantly higher than in group 1: 40% vs 14%, respectively, after 10 days (p = 0.0034); 48 vs 18% after 30 days (p = 0.0014); and 54% vs 24% after 1 year (p = 0.0021). Thrombolytic treatment was used in only 40% of the patients in group 2. In group 2, acute heart failure (HF) (Killip class III and IV) was diagnosed more frequently than in group 1 (28% vs 12%, p = 0.034). In patients with Killip class I/II HF, mortality in patients in group 2 and group 1 was 22% vs 9%, at 10 days; 31% vs 14% at 30 days; and 39% vs 20% at 1 year. In patients with Killip class III/IV HF, mortality was 86% vs 50%, at 10 days; 93% vs 50% at 30 days; and 93% vs 50% at 1 year, respectively (all differences NS). In multivariate analysis adjusted for the differences between groups, HF (a negative effect) and a successful PCI (a positive effect) were independent predictors of 1-year survival. Successful primary PCI in STEMI patients above 80 years of age resulted in a reduction of early and long-term mortality compared to the medically treated patients. The benefits of PCI treatment accrued during the follow-up. In patients treated in the tertiary reference centre in whom PCI was not successful or was not deemed feasible, prognosis was similar to that in the medically treated patients. The latter patients rarely received thrombolytic treatment.
- 1 October 2010
- Vol. 68 (10) , 1133-9
Quality of life and depression in patients with different patterns of atrial fibrillation.
Atrial fibrillation (AF) is difficult to cure and significantly affects quality of life was well as emotional status of patients. to evaluate quality of life and depression level in patients with various patterns of AF. we studied 150 consecutive patients with AF aged 35-83 years, including 61 patients with paroxysmal AF, 46 patients with persistent AF, and 43 patients with permanent AF. The control group included 70 healthy persons (mean age: 55.5 ± 14.5 years). Quality of life was estimated using the Nottingham Health Profile questionnaire. Risk of depression occurrence was estimated using the Beck Depression Inventory scale. Physical abilities, energy level, pain, emotional reactions, sleep, social isolation, problems with work, family life and sexual life were analysed. the mean age of patients with paroxysmal AF was higher in comparison to patients with permanent AF (68.4 ± 9.4 vs 62.0 ± 9.2 years, p < 0.05). In patients with all AF forms, the prevalence of symptoms indicating depression was significantly higher in comparison with control group (paroxysmal AF: 10.8 ± 5.8%, persistent AF: 10.0 ± 6.4%, permanent AF: 10.1 ± 7.2% vs 5.7 ± 5.8% in controls, p < 0.01). The level of depression was higher in women regardless of AF form (p < 0.005). Patients with paroxysmal and permanent AF had lower scores of emotional reactions (p < 0.05) and social isolation (p < 0.05) in comparison with the control group. All patients with AF had lower scores of energy level in comparison with the control group (paroxysmal AF: 1.2 ± 0.2, persistent AF: 1.1 ± 0.2, permanent AF: 1.2 ± 0.2 vs 0.5 ± 0.1 in controls, p < 0.005). Patients with paroxysmal, persistent and permanent AF had greater degree of activity limitations than the control group (1.8 ± 0.2, 1.7 ± 0.3, 2.1 ± 0.3, respectively, vs 1.0 ± 0.2, p < 0.005). Limitations of work were detected in 28.6-35.9% of patients with various forms of AF, sex life disturbances in 23.8-33.9% of patients, and family life problems in 10.3-21.4% of patients. The lowest results of these scores were noted in patients with paroxysmal AF. atrial fibrillation, independently of its form, has substantial impact on the risk of depression occurrence. Patients with paroxysmal and permanent AF had lower self-evaluation of their energy level. In all studied groups of AF patients, the arrhythmia significantly limited quality of life, especially sexual life as well as professional and home activity.
- 1 October 2010
- Vol. 68 (10) , 1133-9
Quality of life and depression in patients with different patterns of atrial fibrillation.
Atrial fibrillation (AF) is difficult to cure and significantly affects quality of life was well as emotional status of patients. to evaluate quality of life and depression level in patients with various patterns of AF. we studied 150 consecutive patients with AF aged 35-83 years, including 61 patients with paroxysmal AF, 46 patients with persistent AF, and 43 patients with permanent AF. The control group included 70 healthy persons (mean age: 55.5 ± 14.5 years). Quality of life was estimated using the Nottingham Health Profile questionnaire. Risk of depression occurrence was estimated using the Beck Depression Inventory scale. Physical abilities, energy level, pain, emotional reactions, sleep, social isolation, problems with work, family life and sexual life were analysed. the mean age of patients with paroxysmal AF was higher in comparison to patients with permanent AF (68.4 ± 9.4 vs 62.0 ± 9.2 years, p < 0.05). In patients with all AF forms, the prevalence of symptoms indicating depression was significantly higher in comparison with control group (paroxysmal AF: 10.8 ± 5.8%, persistent AF: 10.0 ± 6.4%, permanent AF: 10.1 ± 7.2% vs 5.7 ± 5.8% in controls, p < 0.01). The level of depression was higher in women regardless of AF form (p < 0.005). Patients with paroxysmal and permanent AF had lower scores of emotional reactions (p < 0.05) and social isolation (p < 0.05) in comparison with the control group. All patients with AF had lower scores of energy level in comparison with the control group (paroxysmal AF: 1.2 ± 0.2, persistent AF: 1.1 ± 0.2, permanent AF: 1.2 ± 0.2 vs 0.5 ± 0.1 in controls, p < 0.005). Patients with paroxysmal, persistent and permanent AF had greater degree of activity limitations than the control group (1.8 ± 0.2, 1.7 ± 0.3, 2.1 ± 0.3, respectively, vs 1.0 ± 0.2, p < 0.005). Limitations of work were detected in 28.6-35.9% of patients with various forms of AF, sex life disturbances in 23.8-33.9% of patients, and family life problems in 10.3-21.4% of patients. The lowest results of these scores were noted in patients with paroxysmal AF. atrial fibrillation, independently of its form, has substantial impact on the risk of depression occurrence. Patients with paroxysmal and permanent AF had lower self-evaluation of their energy level. In all studied groups of AF patients, the arrhythmia significantly limited quality of life, especially sexual life as well as professional and home activity.